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was tolerability related to the number of withdrawals patients in each study, due 
to the presence of adverse events or treatment failure. The analyses were per-
formed using software Addis (v.1.16.5) and RevMan (5.1). Results: A total of 979 
documents were initially identified and 11 of them met the selection criteria to 
meta-analysis. No significant differences were observed between the number of 
withdrawals patients due adverse events in any meta-analysis of control ver-
sus intervention. The odds ratio ranged from 0.68 (CI 032-1.45) to placebo versus 
asenapine, 1.37 (CI 0.29-1.33) to placebo versus iloperidone and 0,71 (CI 0,36-1,41) 
to placebo versus lurasidone. However, all drugs were superior to their respective 
controls for the outcome of number of withdrawals by treatment failure, with 
odds ratio between 1.70 (CI 1.21-2.39) and 2.36 (CI 1.36-4.07). These results suggest 
that there is a higher effectiveness among patients for the treatment interven-
tion that should be evaluated through clinical responses. Heterogeneity between 
studies (evaluated by I2 values) were low or moderate, not superior than 39,5% 
in any meta-analysis. ConClusions: Information and knowledge reunion and 
confrontation on the tolerability profile of a particular drug allows safer decisions 
over the therapeutic approach, focused on patient’s interest which directly reflects 
on treatment follow-through and therapy effectiveness. In this study, we report 
evidence on asenapine, iloperidone and lurasidone greater tolerability profile 
compared to placebo in schizophrenia treatment.
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objeCtives: To simulate the optimal budget allocation for first line antipsychotic 
medications in schizophrenia which minimize relapses. Methods: From the 
health system perspective, a Lagrange budget optimization analysis was per-
formed with the SOLVER application in order to estimate the efficient market 
share of first line antipsychotics (oral, depot and Long Acting Injectable - LAI). 
The following parameters were gathered and validated in five psychiatric institu-
tions: target population, current market share, adherence to the treatment, risk 
of relapse, and the usage of outpatient and inpatient care resources. The tariffs 
were taken from official and institutional sources. The time frame was one year. 
Two scenarios were compared: the current and the optimum. Results: Current 
scenario: assuming a budget constraint of USD 250,000, a target population of 
381 patients and a baseline market share (oral 95.7%, depot 2.3% and LAI 2.0%), 
150 relapses were avoided (savings of USD 320,086). With the Optimum scenario 
market share [oral 83.0%, depot 4.0% and LAI 13.0%], 208 relapses were avoided 
[savings of USD 445,986]. ConClusions: Assuming a fixed budget for first line 
antipsychotic treatments, increasing the usage of LAI enable a budget optimiza-
tion and relapses minimization.
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objeCtives: To quantify the cost of schizophrenia relapse in Argentina from the 
perspective of the public and third party payer. Schizophrenia is a chronic, severe, 
and disabling mental disorder that significantly affects a person’s thought processes 
and emotional responsiveness. Due to the debilitating nature of the illness, people 
with schizophrenia have a relatively high utilization rate of health care and mental 
health services. Although there is currently no cure for schizophrenia, treatment 
is available to manage the symptoms and reduce the risk of relapse. However, poor 
adherence to treatment remains a significant issue with evidence showing that up 
to 60% of patients are partially or totally non-adherent to their prescribed oral treat-
ments. Methods: A cost of disease study was performed including direct, indi-
rect and transference costs of relapses in schizophrenia. Bottom-up and top down 
methodologies were used to obtain direct costs of health care services consumed by 
this population. Validation of clinical criteria took place with local KOLs. Burden of 
disease was calculated using Disability Adjusted Life Years (DALY) supported by the 
CEPAL. The impact on the local economy was also included by obtaining transfer-
ence costs. Results: This study estimated that there were 415,870 patients with 
schizophrenia, from which 87.333 experienced some episode of relapse in Argentina. 
This corresponds to 21% of patients with schizophrenia. The total potential avoid-
able direct healthcare cost of relapse, total indirect cost over a 12 month period, and 
percentage of people not employed due to relapsing disease were calculated and 
will be presented in the publication. ConClusions: Argentinian decision makers 
in health can largely benefit by controlling relapses for these types of patients. 
This study is one of the first approaches at quantifying the impact of the disease 
and its relapse.
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objeCtivos: Estimar los costos de enfermedades mentales prevalentes (EMP) 
en los establecimientos del Ministerio de Salud del Perú. MetodologíAs: Se 
realizó una evaluación económica parcial de tipo costo de enfermedad (CE). La 
población de estudio fue una cohorte hipotética de pacientes afiliada al Seguro 
Público de Salud (Seguro Integral de Salud) en el Perú. Los costos se estimaron 
symptoms (PCC -0.25 for positive symptoms and -0.29 for negative symptoms; 
p< 0.001). Improvement in negative symptoms was highly correlated to improve-
ment in QoL (PCC 0.33; p< 0.0001). The regression model analysing the influence 
of both positive and negative symptoms on QoL at baseline was confirmative and 
showed a greater beta coefficient (higher influence) for negative symptoms com-
pared with positive symptoms [(3.9 (se 0.14) versus 2.9 (se 0.13)]. Another model 
found that patients with greater negative symptoms at baseline experienced lower 
improvement in QoL (beta coefficient -0.81; se 0.11; p< 0.001). ConClusions: In 
patients with schizophrenia negative symptoms seem to have a larger influence 
onself-perceived QoL than positive symptoms. Improvement in negative symp-
toms is highly associated with improvements in QoL.
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objetivos: O objetivo desse estudo é revisar a evidência científica disponível sobre 
a eficácia e segurança dos antidepressivos de segunda geração duloxetina, venla-
faxina e trazodona em comparação à fluoxetina para o tratamento do Transtorno 
Depressivo Maior (TDM) em adultos. Métodos: Buscaram-se revisões sistemáticas 
(RS) de ensaios clínicos que comparassem a eficácia e segurança dos medicamentos 
duloxetina, venlafaxina e trazodona frente à fluoxetina para o tratamento do TDM nas 
bases de dados PUBMED, LILACS, CENTRAL e CRD. A avaliação da qualidade da evidên-
cia foi realizada por meio da ferramenta GRADE. Avaliações de Tecnologias de Saúde 
(ATS) e guias terapêuticos foram pesquisados em sites de agências nacionais e inter-
nacionais. O custo mensal do tratamento foi calculado para aquisições por compras 
públicas. ResultAdos: Foram incluídas 12 RS com meta-análise. Em geral os estudos 
apresentaram baixa qualidade metodológica. Nove estudos apontaram superioridade 
do tratamento com venlafaxina frente à fluoxetina na redução de 50% dos sintomas. 
A razão de resposta (RR ou OR) entre os grupos venlafaxina e fluoxetina variou entre 
1,12 e 1,36. Em geral, a taxa de abandono e a incidência de eventos adversos foram 
maiores para os grupos venlafaxina e duloxetina, comparados ao grupo fluoxetina. As 
4 ATS encontradas concluíram que os antidepressivos de segunda geração possuíam 
eficácia comparável à da fluoxetina, com maior custo associado. O tratamento com a 
fluoxetina corresponde ao menor valor. ConClusões: Verificou-se baixa qualidade 
da evidência dos resultados, menor custo de tratamento com o medicamento fluox-
etina e recomendações das Agências de ATS e guias terapêuticos quanto a eficácia 
comparável entre os antidepressivos e indicação da fluoxetina no diagnóstico inicial 
do TDM. Recomenda-se que a fluoxetina seja o medicamento de primeira escolha 
para o tratamento do TDM em pacientes adultos e em caso de resposta inadequada, 
a venlafaxina poderia ser utilizada como segunda escolha.
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objeCtives: To evaluate the efficacy and safety of methylphenidate com-
pared to other pharmacological alternatives or placebo in the treatment of 
ADHD. Methods: Health technology assessments (HTA), randomized clinical 
trials (RCT) or systematic reviews (SR) of RCT were systematically researched. 
Inclusion criteria were placebo or pharmacological intervention as comparators, 
and children or adolescents as population. Studies about different dosis or pres-
entations of methylphenidate were also selected. Results: One ECR, four SR and 
two HTA were selected comparing methylphenidate to placebo, atomoxetine, bus-
pirone, dexamphetamine. Methylphenidate was superior to placebo in the index of 
hyperactivity detected by parents and teachers, behavior during the execution of 
tasks, productivity in classroom and in precision of the activities. Response rates to 
treatment and abandonment were better as compared to atomoxetine. Compared 
to buspirone, methylphenidate was shown to be more effective in reducing the 
symptoms of ADHD. Benefits of methylphenidate on dexamphetamine are incon-
clusive. Low dose methylphenidate was superior to high dose in behavior improve-
ment on the execution of tasks. There was no difference between long and short 
acting presentations. Regarding security: anorexia, insomnia, migraines, stomach 
pain and dizziness were often associated with methylphenidate. ConClusions: 
Primary studies showed methodological limitations such as low quality, short fol-
low up and low capacity of generalization. The evaluation of the results should be 
cautious. It is necessary to find a balance between benefits and risks before start-
ing the administration of methylphenidate in children and adolescents, especially 
in long-term treatments.
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objeCtives: Evaluate the tolerability of three antipsychotic drugs – asenapine, 
iloperidone and lurasidone – in the treatment of schizophrenia. Methods: An 
eletronic search was performed in Medline (Pubmed), Cochrane Library, Scopus, 
Science Direct and Scielo. A systematic review and meta-analysis of randomized 
controlled trials (RCTs) comparing the use of any of the above-mentioned drugs 
versusplacebo in schizophrenia was realized. Publications available in English, 
Portuguese, Spanish, French and German were evaluated. The main outcome 
